Navigation Links
Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo
Date:5/23/2011

SEATTLE, Wash., May 23, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 18-month data from its Phase 2 CUPID clinical trial of MYDICAR® demonstrated continued improvements in clinical outcomes in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

"We are pleased to present data from the long-term follow-up portion of the CUPID trial with MYDICAR demonstrating reduced hospitalizations and other cardiovascular events at 18 months after treatment," said Krisztina Zsebo, Ph.D., CEO and President of Celladon, who presented the study's long-term follow-up results during the American Society of Cell and Gene Therapy 2011.

The study of 39 patients met its primary safety and efficacy endpoints at 6 months for high dose MYDICAR versus placebo.  Additionally, after 12 months of receiving a single infusion of MYDICAR, patients treated with the highest dose versus placebo had an 88 percent risk reduction (Hazard Ratio = 0.12, P=0.003), of major cardiovascular events such as:

  • Death
  • Need for left ventricular assist device (LVAD) or cardiac transplant
  • Episodes of worsening of heart failure

Additionally, the 18-month CUPID data from long-term follow-up demonstrate a durable benefit in preventing major cardiovascular events.

The 12 month data presented in 2010 showed that heart failure, which is a progressive disease, became stabilized in high dose MYDICAR-treated patients: heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function essentially improved or remained stable while these parameters deteriorated substantially in patients treated with placebo and concurrent optimal drug and device therapy.

We believe the efficacy sustained in patients over a 18-mon
'/>"/>

SOURCE Celladon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
2. Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
3. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
4. Gumz to Retire as President and CEO of Olympus Corporation of the Americas
5. Medication Delivery Innovator Baxa Corporation Offers Best Practices for Administering Over-the-Counter Liquid Medicine to Babies and Toddlers
6. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
7. TechPrecision Corporation Receives $1.6 Million in New Orders from Existing Customers
8. SenSage Named Cerner Corporations Accelerate Partner of the Year
9. Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation
10. Henry Schein Ranks #317 in 2011 Fortune 500 Ranking of Americas Largest Corporations
11. Omeros Corporation Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
(Date:7/13/2014)... According to the Kidney Disease Solution book review ... guide on what to do to eliminate the root ... in its review that readers can easily learn what foods ... kidney health. Vkool also informs in its Kidney Disease Solution ... kidney functions naturally. The book consists of a collection of ...
(Date:7/13/2014)... 13, 2014 A Xarelto lawsuit ... LLC to provide consumers with the most current information ... of the blood-thinning medication, as well as the ... courts around the country. The law firm is now ... suffered from life-threatening internal bleeding and related complications while ...
(Date:7/13/2014)... WA (PRWEB) July 13, 2014 ... Woolcott, who commented, “As a parent of a special ... underserved need in the Seattle community for contemporary special ... provide an important alternative to students and families in ... best practices and environment for special education. We welcome ...
(Date:7/13/2014)... Arbor, MI (PRWEB) July 13, 2014 If ... learning program he has just launched at http://www.HealthYourself101.com ... of visceral obesity. , Power has set out to ... its ill effects that’s actually – dare we say it? ... “The program,” says Power, “aims to engage the remote learner ...
(Date:7/13/2014)... July 13, 2014 According to the ... this is a comprehensive guide that features a series ... with KP (keratosis pilaris). This guide consists of ... Is Keratosis Pilaris? ,     Chapter 2: What Cause ... If I Have KP? ,     Chapter 4: Keratosis ...
Breaking Medicine News(10 mins):Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3
... Italy, May 29th, 2008 - Children who can read and ... individual sounds within words may still be poor spellers. ... Cortex, Elizabeth Eglinton and Marian Annett, at the School of ... spellers is more likely to be right-handed than other poor ...
... Educates Consumers about Urinary Health, CROMWELL, Conn., May 29 ... (UTIs) are the second most common type,of infection in the ... year. One-third of women will be diagnosed with a UTI ... get at least one in their lifetime.(2),However, many women do ...
... Up To Three Times as Many Calories as,Hand-Held, ... Nintendo Wii, are quickly becoming the most coveted gaming,systems ... to,be helpful in encouraging youth to exercise, as profiled ... of the American College of,Sports Medicine (ACSM)., One ...
... to Remain Stable or Improve in 83% of Patients ... ... Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer of real-time medical imaging and ... Hospital in Milan, Italy reported independent 12-month follow-up data,on patients treated ...
... Human immune response in wildland firefighters study to be presented ... American College ... Montana Center for Work,Physiology and Exercise Metabolism (Montana WPEM) will ... American College of Sports,Medicine, showing that wildland firefighters who consumed ...
... TOKYO, May 29 ALOKA announced today new ... the 20th Congress of,European Federation of Societies for ... 3rd of June 2008, in Timisoara, Romania. The ... excellent image quality,with comprehensive functions. High image quality ...
Cached Medicine News:Health News:AZO Answers the Burning Question: What's Up Down There? 2Health News:AZO Answers the Burning Question: What's Up Down There? 3Health News:AZO Answers the Burning Question: What's Up Down There? 4Health News:Kids' Energy Expenditure High in Active Video Games 2Health News:Novadaq Updates on OPTTX Data Reported at Euroretina 2Health News:Novadaq Updates on OPTTX Data Reported at Euroretina 3Health News:Novadaq Updates on OPTTX Data Reported at Euroretina 4Health News:Montana Center for Work Physiology and Exercise Metabolism Presents Firefighter Health Study 2Health News:ALOKA to Unveil a New Compact 'ProSound' Diagnostic Ultrasound System 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: